Pew Responds to White House's Drug Pricing Blueprint Information Request

The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).

Pew’s response to the RFI addresses the following topics:

• Federal program incentives.
• Drug pricing structures and incentives.
• Proposals to reform the Medicare Part B Competitive Acquisition Program.
• Price reporting requirements and incentive structures.
• Cost-shifting and cross-subsidization.
• Generic drug pricing and development.
• Pharmacy benefit managers and rebates.
• 340B Drug Pricing Program.
• Patient cost-sharing.